89
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Inflammatory bowel disease (IBD) is characterised by chronic intestinal inflammation, resulting from dysregulation of the mucosal immune system and compromised intestinal epithelial barrier function. The bile salt, nuclear farnesoid X receptor (FXR), was recently implicated in intestinal antibacterial defence and barrier function. The aim of this study was to investigate the therapeutic potential of FXR agonists in the treatment of intestinal inflammation in complementary in vivo and in vitro models.

          Related collections

          Author and article information

          Journal
          Gut
          Gut
          BMJ
          1468-3288
          0017-5749
          Apr 2011
          : 60
          : 4
          Affiliations
          [1 ] Department of Gastroenterology and Hepatology, UMC Utrecht, The Netherlands.
          Article
          gut.2010.212159
          10.1136/gut.2010.212159
          21242261
          2a0589a6-263b-4022-b9bc-c6ddbb59b315
          History

          Comments

          Comment on this article